Crescent Biopharma, Inc.
NCM: CBIOLive Quote
About Crescent Biopharma, Inc.
Healthcare
Biotechnology
Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics. The company was formerly known as GlycoMimetics, Inc. The company was founded in 2024 and is headquartered in Waltham, Massachusetts.
📊 Fundamental Analysis
Crescent Biopharma, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -160.7%, which indicates that capital utilization is currently under pressure.
At a current price of $18.17, CBIO currently sits at the 47th percentile of its 52-week range (Range: $8.72 - $29.00).
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Debt/Equity
Elevated
🔴
Return on Equity
Weak
Key Financials
Market Cap
$496.29M
Trailing P/E
--
Forward P/E
-5.08
Beta (5Y)
--
52W High
$29.00
52W Low
$8.72
Avg Volume
211K
Day High
Day Low
📡 Subscribe to ZcoreAI updates
Join the list to get access to:
- Z-Score signals at market open
- New app features and updates
- Exclusive promo for ZcoreAI App